Document Detail

The effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction.
MedLine Citation:
PMID:  19944317     Owner:  NLM     Status:  In-Process    
BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) plays an important role in the pathogenesis of acute coronary syndrome. We have recently demonstrated that the administration of edaravone before reperfusion attenuated reperfusion injury in patients with acute myocardial infarction (AMI).
METHODS: Plasma MCP-1 levels were measured in 45 consecutive patients with AMI (edaravone group, n=25; control group, n=20). In the edaravone group, 30 mg edaravone was intravenously infused just before reperfusion. Plasma samples were obtained before and at 24h, 3, 5, 7, and 14 days after reperfusion. Cardiovascular events were defined as cardiac death, subacute thrombosis, or fatal arrhythmia. Heart failure requiring rehospitalization was evaluated at 12 months after reperfusion.
RESULTS: Plasma MCP-1 levels were not different between the two groups before reperfusion. Compared with the placebo group, the edaravone group had statistically lower maximum creatine kinase-MB levels (218±31 IU/l versus 145±21 IU/l, p<0.05) and plasma MCP-1 levels on day 3 after reperfusion (873±118 pg/ml versus 516±66 pg/ml, p<0.05). Heart failure requiring rehospitalization occurred in four patients in the control group, but did not occur in the edaravone group (p<0.05). At 12 months after reperfusion, left ventricular ejection fraction was statistically higher in the edaravone group than in the control group (62±2% versus 54±3%, p<0.05).
CONCLUSION: Edaravone suppressed plasma MCP-1, improved left ventricular ejection fraction, and reduced rehospitalization due to heart failure. Suppression of plasma MCP-1 level by edaravone might induce better prognosis for AMI patients.
Yoshinori Nakamura; Yoshihiro Yamada; Hideki Shimomura; Yasuhiro Nagayoshi; Kenichi Tsujita; Takuro Yamashita; Masaya Fukuda; Keisuke Ohba; Hisato Nako; Yuji Ogura; Tadasuke Chitose; Munetaka Yamaguchi; Takeshi Nagata; Hirofumi Soejima; Koichi Kaikita; Seigo Sugiyama; Hisao Ogawa
Related Documents :
14726067 - Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated...
14730097 - Nitric oxide- and prostaglandin-mediated cardioprotection by bradykinin in myocardial i...
11937297 - Polynitroxyl-albumin (pna) enhances myocardial infarction therapeutic effect of tempol ...
8287867 - Rationale for trimetazidine administration in myocardial ischaemia-reperfusion syndrome.
1689327 - Response of the coronary vasculature to myocardial hypertrophy.
24710707 - Prognostic value of coronary ct angiography on long-term follow-up of 6.9 years.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-08-20
Journal Detail:
Title:  Journal of cardiology     Volume:  54     ISSN:  1876-4738     ISO Abbreviation:  J Cardiol     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8804703     Medline TA:  J Cardiol     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  416-24     Citation Subset:  IM    
Fukuoka Tokushukai Medical Center, 4-5 Sukukita, Kasuga, Fukuoka 816-0864, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Plasma granzyme B as a predicting factor of coronary artery disease--clinical significance in patien...
Next Document:  Transnasal transesophageal echocardiography in the detection of left atrial thrombus.